NASDAQ:VSAR Versartis (VSAR) Stock Price, News & Analysis → The 2024 Gold Rush: Unleashing Market Potential (From Priority Gold) (Ad) Free VSAR Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$1.18▼$1.3050-Day Range$1.19▼$1.1952-Week Range$1.14▼$2.76Volume349,963 shsAverage Volume479,436 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Versartis alerts: Email Address Ad Crypto 101 MediaElon Musk Secret Crypto Plot ExposedReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.Click here now to get your copy. About Versartis Stock (NASDAQ:VSAR)Aravive, Inc. operates as a clinical stage biotechnology company. The firm engages in the development of new therapies that target important survival pathways for both advanced solid tumors as well as hematologic malignancies. Its product candidate, Aravive-S6, is a soluble Fc-fusion protein designed to block the activation of the GAS6-AXL signaling pathway by intercepting the binding of GAS6 to its receptor AXL which also promotes metastasis, cancer cell survival, resistance to treatments and immune suppression. The company was founded on December 10, 2008 and is headquartered in Houston, TX.Read More Ad Crypto 101 MediaElon Musk Secret Crypto Plot ExposedReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.Click here now to get your copy. VSAR Stock News HeadlinesJuly 21, 2023 | thestreet.com16 Biopharma Companies Besides Medivation That Are Attractive TargetsDecember 28, 2022 | thestreet.comDon't Tell Anyone: Insiders Are Buying These Stocks Like CrazyMay 11, 2024 | Colonial Metals (Ad)Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. October 11, 2022 | finance.yahoo.comZluri Hires Todd Dekkinga as Chief Information Security Officer - Yahoo FinanceMay 9, 2022 | seekingalpha.comAscendis Pharma: Biotech Bear Provides Attractive Entry Point - Seeking AlphaMarch 21, 2022 | thestreet.comVersartis Price Gains on Drug Approval, eHealth Rises: Tech Winners & LosersSeptember 22, 2021 | prnewswire.comAmphista Therapeutics Appoints New Chairman, Joshua T. Brumm - PRNewswireSeptember 3, 2021 | finance.yahoo.comCidara Therapeutics Appoints Preetam Shah, Ph.D., MBA, as Chief Financial Officer and Chief Business Officer, and Shane Ward as Chief Legal Officer and Corporate Secretary - Yahoo FinanceMay 11, 2024 | Banyan Hill Publishing (Ad)CEO of Biggest AI Chipmaker Just Dropped a Bombshell…Nvidia’s CEO calls it the “next amazing revolution” … and even declared it “is going to be flat out of the biggest [revolution] ever.” Jeff Bezos, Bill Gates, and Mark Zuckerberg have invested billions in it.September 2, 2021 | streetinsider.comCidara Therapeutics (CDTX) Appoint Preetam Shah as CFO and CBO, and Shane Ward as Chief Legal Officer and Corporate Secretary - StreetInsider.comJuly 22, 2021 | entrepreneur.com3 Biotech Stocks Wall Street Predicts Will Rally by More Than 170% - EntrepreneurSee More Headlines Receive VSAR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Versartis and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/07/2018Today5/11/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:VSAR CUSIPN/A CIK1513818 Webwww.versartis.com Phone(936) 355-1910FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableOptionable BetaN/A 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesGail Frances McIntyrePresident, Chief Executive Officer & DirectorVinay ShahChief Financial OfficerReshma RangwalaChief Medical OfficerAmy FrankeVice President-Clinical OperationsRandy AndersonSenior Vice President-Data SciencesKey CompetitorsContext TherapeuticsNASDAQ:CNTXGrifolsNASDAQ:GRFSLAVA TherapeuticsNASDAQ:LVTXMainz BiomedNASDAQ:MYNZNLS PharmaceuticsNASDAQ:NLSPView All Competitors VSAR Stock Analysis - Frequently Asked Questions How were Versartis' earnings last quarter? Versartis, Inc. (NASDAQ:VSAR) released its earnings results on Tuesday, August, 7th. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, topping the consensus estimate of ($0.96) by $0.69. What other stocks do shareholders of Versartis own? Based on aggregate information from My MarketBeat watchlists, some companies that other Versartis investors own include Progenics Pharmaceuticals (PGNX), ZIOPHARM Oncology (ZIOP), Bausch Health Companies (BHC), Genocea Biosciences (GNCA), Novavax (NVAX), Cara Therapeutics (CARA), Flexion Therapeutics (FLXN), SCYNEXIS (SCYX) and Synergy Pharmaceuticals (SGYP). This page (NASDAQ:VSAR) was last updated on 5/11/2024 by MarketBeat.com Staff From Our PartnersThe Crypto 9-5 Escape PlanCrypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldThe A.I. story nobody is telling you (Read ASAP)TradeSmithA.I. is a Tidal Wave - Here’s What to BuyChaikin AnalyticsGold Set to EXPLODE!Gold Safe ExchangeDems have chosen Biden replacement?Paradigm PressGlobal crypto currency reset (41 major banks signed up)Stansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Versartis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
